Vittal Mogasale

Cost-effectiveness of Selected Immunisation Programs in Australia

Economic evaluation of influenza and hepatitis B immunization programs in Australia

• Broschiertes Buch

Produktbeschreibung

Health care costs are on the rise in Australia. Rational decisions using cost-effectiveness analyses are necessary to prioritise health interventions for the allocation of limited resources. Immunisation is an important component of preventive health care intervention and its cost-effectiveness analyses are useful in prioritising the choices. This book describes economic evaluation of two immunisation interventions in Australia: influenza and hepatitis B. We have analysed cost-effectiveness of reducing universal influenza vaccination age threshold to 50 from the current 65 using a decision tree model and cost-effectiveness of various hepatitis B infant vaccination strategies using a micro-simulation model. Here we describe the strength of the evidence to reduce universal influenza vaccination age threshold. Our results also suggest that the current hepatitis B vaccination strategy in Australia is an expensive one, but yields maximum health gain in general population. Is that the best choice? How good is Australian hepatitis B immunization strategy for indigenous population? Do we have alternative cost-effective choices? This book tries to explore all these questions.

Produktdetails

• Verlag: LAP Lambert Academic Publishing
• Aufl.
• Seitenzahl: 128
• Erscheinungstermin: 17. Oktober 2011
• Englisch
• Abmessung: 220mm x 150mm x 8mm
• Gewicht: 185g
• ISBN-13: 9783846504048
• ISBN-10: 3846504041
• Artikelnr.: 34326785

Autorenporträt

Dr.Vittal Mogasale, M.B.B.S., M.P.H., Ph.D., is a Physician, Public Health Professional and Health Economist who has worked for the control of communicable diseases over a decade in India. Now he works with International Vaccine Institute, Seoul to facilitate the introduction of new and improved vaccines in developing countries.